Celgene Settles Whistle-Blower Fraud Suit for $280 Million - Bloomberg

Bloomberg

Celgene Settles Whistle-Blower Fraud Suit for $280 Million Bloomberg Even after the FDA approved Thalomid for multiple myeloma in the mid-2000s, Celgene continued to promote it for other forms of cancer, including cervix, thyroid and brain, Brown said in the 2010 complaint. Since Thalomid's early safety labels didn't ... and more »

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vZdUXF
via IFTTT